C. Dans-le-groupe, ». Naïf-de-traitement, and L. Taux, ADN circulant libre était associé au score AFP (p=0.05, OR= 0.34 [IC95% : 12.87;348.71]). La figure 3 montre que les patients avec un score AFP >2

A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011.
DOI : 10.3322/caac.20107

J. Llovet, A. Burroughs, J. Bruix, and . Hepatocellular-carcinoma, Hepatocellular carcinoma, The Lancet, vol.362, issue.9399, pp.1907-1924, 2003.
DOI : 10.1016/S0140-6736(03)14964-1

D. Parkin, P. Pisani, and J. Ferlay, Estimates of the worldwide incidence of 25 major cancers in 1990, International Journal of Cancer, vol.64, issue.6, pp.827-868, 1999.
DOI : 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P

F. Bosch, J. Ribes, M. Diaz, and R. Cleries, Primary liver cancer: Worldwide incidence and trends, Gastroenterology, vol.127, issue.5, pp.5-16, 2004.
DOI : 10.1053/j.gastro.2004.09.011

D. Parkin, F. Bray, J. Ferlay, and P. Pisani, Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.49, issue.1, pp.74-108, 2002.
DOI : 10.3322/canjclin.49.1.33

J. Llovet, J. Zucman-rossi, E. Pikarsky, B. Sangro, M. Schwartz et al., Hepatocellular carcinoma, Nature Reviews Disease Primers, vol.21, p.16018, 2016.
DOI : 10.1038/nrdp.2016.18

J. Bruix, M. Sherman, J. Llovet, M. Beaugrand, R. Lencioni et al., Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Journal of Hepatology, vol.35, issue.3, pp.421-451, 2001.
DOI : 10.1016/S0168-8278(01)00130-1

A. Singal and H. El-serag, Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice, Clinical Gastroenterology and Hepatology, vol.13, issue.12, pp.2140-51, 2015.
DOI : 10.1016/j.cgh.2015.08.014

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618036

T. Murakami, T. Kim, H. Oi, H. Nakamura, H. Igarashi et al., Detectability of Hypervascular Hepatocellular Carcinoma by Arterial Phase Images of MR and Spiral CT, Acta Radiologica, vol.36, issue.4, pp.372-378, 1995.
DOI : 10.3109/02841859509173391

P. Lisa, V. Waller, N. Deshpande, and . Pyrsopoulos, Hepatocellular carcinoma : A comprehensive review, World J Hepatol, vol.7, pp.2648-63, 2015.

L. Diaz, . Jr, and A. Bardelli, Liquid Biopsies: Genotyping Circulating Tumor DNA, Journal of Clinical Oncology, vol.32, issue.6, pp.579-86, 2014.
DOI : 10.1200/JCO.2012.45.2011

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820760

P. Song, J. Xia, Y. Inagaki, K. Hasegawa, Y. Sakamoto et al., Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma, World Journal of Gastroenterology, vol.22, issue.1, pp.262-74, 2016.
DOI : 10.3748/wjg.v22.i1.262

Y. Tomimaru, H. Eguchi, H. Nagano, H. Wada, S. Kobayashi et al., Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma, Journal of Hepatology, vol.56, issue.1, pp.167-75, 2012.
DOI : 10.1016/j.jhep.2011.04.026

S. Leon, B. Shapiro, D. Sklaroff, and M. Yaros, Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, vol.37, pp.646-50, 1977.

M. Stroun, J. Lyautey, C. Lederrey, A. Olson-sand, and P. Anker, About the possible origin and mechanism of circulating DNA, Clinica Chimica Acta, vol.313, issue.1-2, pp.139-181, 2001.
DOI : 10.1016/S0009-8981(01)00665-9

S. Holdenrieder and P. Stieber, Apoptotic markers in cancer, Clinical Biochemistry, vol.37, issue.7, pp.605-622, 2004.
DOI : 10.1016/j.clinbiochem.2004.05.003

C. Bettegowda, M. Sausen, R. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, p.224, 2014.

Y. Tokuhisa, N. Lizuka, I. Sakaida, T. Moribe, N. Fujita et al., Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma, British Journal of Cancer, vol.28, issue.10, pp.1399-403, 2007.
DOI : 10.1038/sj.bjc.6604034

K. Chen, H. Zhang, L. Zhang, S. Ju, J. Qi et al., Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma, World Journal of Gastroenterology, vol.19, issue.20, pp.3143-3149, 2013.
DOI : 10.3748/wjg.v19.i20.3143

N. Ren, Q. Ye, L. Qin, B. Zhang, Y. Liu et al., Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients, World Journal of Gastroenterology, vol.12, issue.24, pp.3911-3914, 2006.
DOI : 10.3748/wjg.v12.i24.3911

D. Sefrioui, N. Sarafan-vasseur, L. Beaussire, M. Baretti, A. Gangloff et al., Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer, Digestive and Liver Disease, vol.47, issue.10, pp.884-90, 2015.
DOI : 10.1016/j.dld.2015.05.023

K. Jung, M. Fleischhacker, and A. Rabien, Cell-free DNA in the blood as a solid tumor biomarker???A critical appraisal of the literature, Clinica Chimica Acta, vol.411, issue.21-22, pp.1611-1635, 2010.
DOI : 10.1016/j.cca.2010.07.032

C. Duvoux, Liver Transplantation for Hepatocellular Carcinoma: A Model Including ??-Fetoprotein Improves the Performance of Milan Criteria, Gastroenterology, vol.143, issue.4, pp.986-94, 2012.
DOI : 10.1053/j.gastro.2012.05.052

URL : https://hal.archives-ouvertes.fr/inserm-00865368

N. Iizuka, I. Sakaida, T. Moribe, N. Fujita, T. Miura et al., Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virusassociated hepatocellular carcinoma, Anticancer research, vol.26, pp.4713-4720, 2006.

T. Wu, D. Zhang, J. Chia, K. Tsao, C. Sun et al., Cell-free DNA: measurement in various carcinomas and establishment of normal reference range, Clinica Chimica Acta, vol.321, issue.1-2, pp.77-87, 2002.
DOI : 10.1016/S0009-8981(02)00091-8

M. Galeazzi, G. Morozzi, M. Piccini, J. Chen, F. Bellisai et al., Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders, Autoimmunity Reviews, vol.2, issue.1, pp.50-55, 2003.
DOI : 10.1016/S1568-9972(02)00101-5